Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-Year follow-up

AIDS Research and Human Retroviruses

Volumn 24, Issue 1, 2008, Pages 24-26

  Santos, Jesús ^a   Palacios, Rosario ^a   Lozano, Fernando ^b   López, Manuel ^c   Gálvez, María Carmen ^d   De La Torres, Javier ^e   López Cortés, Luis Fernando ^f   Ríos, María José ^g   Rivero, Antonio ^h  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL TORRECÁRDENAS   (Spain)

^e HOSPITAL COSTA DEL SOL   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DIDANOSINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 38149017968     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0142     Document Type: Article

References (8)

1. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201.
2. Pozniak AL, Gallant JE, DeJesus E, et al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535-540.
3. Reliquet V, Allavena V, Francois-Brunet C, et al.: Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med 2006;7:431-436.
4. Santos J, Palacios R, López M, et al.: Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: The VESD study. HIV Clin Trials 2005;6:320-328.
5. DeJesus E, Herrera G, Teofilo E, et al., for the CNA30024 Study Team: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004;39:1038-1046.
6. Saag MS, Cahn P, Raffi F, et al., for the FTC-301A Study Team: Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients: A randomized trial. JAMA 2004;292:180-189.
7. Eron J, da Silva B, King M, et al.: Lopinavir/ritonavir (Kaletra) in antiretroviral-naïve patients: 5 year follow-up. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, September 2003 (Poster H-844).
8. Palacios R, Aguilar I, Hidalgo A, and Santos J. Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. Expert Rev Anti Infect Ther 2006;4:965-971.